Remeditex Ventures

Soliton, Inc. is a medical device company based in Houston, Texas, that specializes in developing and commercializing products leveraging its proprietary rapid acoustic pulse (RAP) technology platform. Founded in 2012, Soliton focuses on creating innovative solutions for various medical applications, including tattoo removal, cellulite reduction, and fibrotic scar treatment. The company has invested significant resources into advancing its technology, which utilizes high-energy acoustic shockwaves to enhance treatment efficacy. Soliton's business model centers around selling its RAP consoles to dermatologists, plastic surgeons, and medi-spas, positioning itself to address substantial market opportunities within the medical aesthetic field. The leadership team comprises experienced professionals with extensive backgrounds in life sciences and medical devices, contributing to the company's goal of transforming aesthetic treatments.

Rodin Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapeutics for cognitive disorders through epigenetic modulation. Founded in 2013, the company leverages insights into key epigenetic regulators of central nervous system (CNS) function to create innovative treatments. Rodin's approach involves harnessing the power of epigenetic regulation, particularly through the modulation of HDAC complexes, to restore synaptic function and enhance neuronal health in patients suffering from degenerative brain diseases. The company is supported by a team experienced in CNS drug development and has access to advanced structural biology capabilities. Rodin Therapeutics operates as a subsidiary of Alkermes Inc.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

Navitor Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing small molecule drugs that target specific nutrient-sensing proteins to modulate mTORC1 activity. This master regulator of cell growth and metabolism plays a crucial role in various age-related diseases. The company's proprietary platform allows for both selective inhibition and activation of mTORC1, offering potential treatments for conditions such as chronic kidney disease, depression, and other metabolic, neurodegenerative, autoimmune, and musculoskeletal diseases. Notable compounds include NV-5138, which activates mTORC1 and modulates sestrin, a natural activator of mTORC1, and the NValog program, which targets chronic kidney disease through selective mTORC1 inhibition. Founded in 2009, Navitor Pharmaceuticals aims to unlock the therapeutic potential of the mTOR pathway for a wide range of diseases.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.

Bi02 Medical, Inc. is a medical device company that specializes in designing, developing, manufacturing, and commercializing innovative solutions for clinical needs. The company's flagship product, the Angel Catheter, is an inferior vena cava (IVC) filter aimed at preventing pulmonary embolism and enabling access to the central venous system in critically ill patients. This catheter-based device allows for the administration of medications, fluids, or blood products, as well as blood sampling and monitoring of central venous pressure. Bi02 Medical operates through a network of distribution partners globally. Founded in 2006, the company is headquartered in San Antonio, Texas, and maintains a research and development and manufacturing facility in Golden, Colorado.

Viridian Therapeutics is a private biotechnology company dedicated to developing treatments for patients with diseases currently underserved by existing therapies. Its primary focus is on advancing therapies for thyroid eye disease, a debilitating orphan condition, using its lead product candidate, VRDN-001, a monoclonal antibody targeting the insulin-like growth factor-1 receptor.

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Houston, Texas, dedicated to the development of novel cellular immunotherapies for treating various cancers, including hematological malignancies and solid tumors. The company is advancing its innovative product candidates, notably BPX-601, an autologous GoCAR-T therapy targeting solid tumors that express prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy aimed at tumors expressing human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control over immune system components, enhancing the efficacy and duration of therapeutic responses. Founded in 2004, Bellicum Pharmaceuticals has established collaborations with several organizations to further its research and development efforts in immunotherapy.

Apollo Endosurgery, Inc. is a medical technology company based in Austin, Texas, specializing in the design, development, and commercialization of innovative medical devices for gastrointestinal health. Founded in 2005, the company focuses on advancing therapeutic endoscopy as a less invasive alternative to traditional surgical procedures, thereby reducing complication rates and overall healthcare costs. Its product portfolio includes the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which enable physicians to place full-thickness sutures and secure tissue approximation through flexible endoscopy. Additionally, Apollo offers the X-Tack Endoscopic HeliX Tacking System and the Orbera Intragastric Balloon, which aids in weight management by reducing stomach capacity. The company's devices cater to gastroenterologists and bariatric surgeons, addressing various gastrointestinal conditions such as acute perforations and chronic fistulas. Apollo Endosurgery's commitment to innovation is rooted in the collaborative efforts of a distinguished group of gastroenterologists and surgeons who aimed to enhance the field of therapeutic endoscopy.

Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company based in Dallas, Texas, dedicated to developing innovative medicines for patients with cancer and other serious conditions. The company focuses on targeting HIF-2a, a transcription factor previously considered difficult to address with small molecules. Its lead drug candidate, PT2977, is an oral HIF-2a inhibitor currently undergoing Phase 2 clinical trials for advanced or metastatic clear cell renal cell carcinoma, and it is being evaluated in various settings, including in patients with von Hippel-Lindau disease-associated renal cell carcinoma and in combination with cabozantinib. Additionally, Peloton is advancing PT2567, another oral HIF-2a inhibitor in preclinical development for non-oncology indications such as pulmonary arterial hypertension. Founded in 2010 and previously known as Damascus Pharmaceutics, Peloton Therapeutics aims to leverage its scientific expertise and collaborations to become a leading biotech company in the region.

BiOptix LLC is an analytical instrumentation company based in Boulder, Colorado, specializing in the development of array-based biomolecule detection systems and molecular interaction analysis instruments. The company’s product offerings include cell array biodetector systems, biochip and optical cartridges, as well as pre-production small footprint and single cell biodetector systems. These products are designed to detect a diverse range of molecules and microorganisms, such as micro RNA, nucleic acids, proteins, antibodies, bacteria, viruses, carbohydrates, lipids, and low molecular weight drugs. BiOptix serves various sectors, including clinical biomarkers and diagnostics, personalized medicine, infectious disease, drug discovery, and academic research, among others. Founded in 2003 and originally named AlphaSniffer, LLC, the company rebranded to BiOptix in May 2008 and operates as a subsidiary of Bioptix, Inc.